Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (63 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > IBRX taking a beating today...
View:
Post by rhodiumd on Apr 24, 2024 3:41pm

IBRX taking a beating today...

Down over 10% for the day after FDA approval... yikes!
Comment by Alamir1111 on Apr 24, 2024 4:04pm
Guess they waiting for tlt btd and than to the moon?
Comment by Kayz88 on Apr 24, 2024 5:11pm
Yeah I've been wondering about that. Not too familiar with their drug other than what I've read on SH and other news releases.  . . So correct me if I'm wrong, but is IBRX's drug kind of like a DLC? Like you need the base game (BCG) to play? If so, how much is the add-on worth? What's the delta in treatment with vs without BCG? 
Comment by Pandora on Apr 24, 2024 9:33pm
The IBRX write up specifically mentions 3 doctors from UBC giving great credits to the Anktiva treatment and suggesting it could become the new BCG standard. I thought Theralase had UBC as a study site? Would these same doctors also be working with the TLT study? Or would they be completely separate? Or was UBC dropped from the TLT study centers? This headline below shows UBC being added but I ...more  
Comment by Pandora on Apr 24, 2024 10:00pm
It seems Dr. Peter Black is a key figure in both releases. Any ideas as to how all this is developing? From the TLT news release: Dr. Peter Black, MD, FRCSC, a Urologic Oncologist at Vancouver General Hospital, a Research Scientist at the Vancouver Prostate Centre, and a Professor in the Department of Urologic Sciences at the University of British Columbia stated "I think this is a great ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

Connect with V.TLT


Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 63 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250